In a new series from CancerNetwork®, two teams of fellows from leading institutions go head-to-head to debate the latest datasets and advances in acute lymphoblastic leukemia.
May 6th 2022
Steven Frommeyer kicks off a new and exciting competitive series from CancerNetwork® and introduces the first 2 teams.
Nikesh Shah, MD, presents a trial published in Lancet Oncology in 2018 on the use of inotuzumab plus mini-CVD in the frontline setting for older patients with ALL.
May 13th 2022
Nikesh Shah, MD, explains a key trial evaluating the efficacy and toxicity of hyper-CVAD in acute lymphocytic leukemia (ALL).
Reem Akel, MD, presents a population-based study on the adoption of pediatric-inspired acute lymphoblastic leukemia (ALL) regimens by adult oncologists.